Hims & Hers Health, Inc. Q3 2025 Financial Results
Hims & Hers Health, Inc., a leading health and wellness platform, has released its financial results for the third quarter of 2025. The company reported significant growth in revenue and subscriber base, reflecting its expanding market presence and strategic initiatives.
Financial Highlights
For the third quarter of 2025, Hims & Hers reported:
- Revenue of $599.0 million, a 49% increase from $401.6 million in Q3 2024.
- Gross margin of 74%, down from 79% in the same period last year.
- Net income of $15.8 million, compared to $75.6 million in Q3 2024, which included a significant tax benefit.
- Adjusted EBITDA of $78.4 million, up from $51.1 million in Q3 2024.
- Net cash provided by operating activities was $148.7 million, compared to $85.3 million in Q3 2024.
- Free Cash Flow remained steady at $79.4 million.
Business and Operational Highlights
The company saw its subscriber base grow to nearly 2.5 million, a 21% increase year-over-year. Monthly online revenue per average subscriber also rose by 19% to $80. Hims & Hers continues to expand its service offerings and partnerships, aiming to establish itself as a global brand in personalized healthcare.
Strategic Initiatives and Corporate Developments
Hims & Hers is in active discussions with Novo Nordisk to potentially offer Wegovy injections and oral Wegovy through its platform, pending FDA approval. This initiative underscores the company's commitment to broadening its healthcare solutions.
Management's Perspective
CEO Andrew Dudum emphasized the company's vision of providing personalized care to millions globally, highlighting the rapid scaling of their platform. CFO Yemi Okupe noted the strong, profitable growth and the company's strategic investments aimed at long-term success.
Future Outlook
For the fourth quarter of 2025, Hims & Hers expects revenue between $605 million and $625 million, with an Adjusted EBITDA of $55 million to $65 million. For the full year, the company projects revenue between $2.335 billion and $2.355 billion, and Adjusted EBITDA between $307 million and $317 million.
Original SEC Filing: Hims & Hers Health, Inc. [ HIMS ] - 8-K - Nov. 03, 2025